abrdn Life Sciences Investors $HQL Shares Sold by Wolverine Asset Management LLC

Key Points

• Wolverine Asset Management cut its position in abrdn Life Sciences Investors by 54.9%, selling 118,399 shares and leaving 97,122 shares worth $1.63 million (0.34% of the company) at the end of the quarter.
• abrdn Life Sciences Investors raised its quarterly dividend to $0.56 (annualized $2.24), implying a 12.5% dividend yield, up from the prior $0.50 quarterly payout.
• Other institutions—including Royal Bank of Canada, NewEdge, First Trust and Raymond James—have increased stakes, leaving total institutional ownership at 32.21%, while the stock recently traded near $17.87 (12‑month range $11.88–$18.10).

Wolverine Asset Management LLC trimmed its position in shares of abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 54.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,122 shares of the company's stock after selling 118,399 shares during the period. Wolverine Asset Management LLC owned 0.34% of abrdn Life Sciences Investors worth $1,630,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HQL. Royal Bank of Canada boosted its stake in abrdn Life Sciences Investors by 53.3% during the 1st quarter. Royal Bank of Canada now owns 73,475 shares of the company's stock valued at $934,000 after purchasing an additional 25,542 shares during the period. NewEdge Advisors LLC lifted its stake in shares of abrdn Life Sciences Investors by 43.1% in the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company's stock worth $412,000 after acquiring an additional 9,785 shares during the period. First Trust Advisors LP lifted its stake in shares of abrdn Life Sciences Investors by 112.2% in the 2nd quarter. First Trust Advisors LP now owns 35,321 shares of the company's stock worth $452,000 after acquiring an additional 18,674 shares during the period. Raymond James Financial Inc. lifted its stake in shares of abrdn Life Sciences Investors by 20.3% in the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company's stock worth $4,816,000 after acquiring an additional 63,429 shares during the period. Finally, Clough Capital Partners L P acquired a new stake in shares of abrdn Life Sciences Investors in the 2nd quarter worth approximately $318,000. 32.21% of the stock is owned by institutional investors and hedge funds.

abrdn Life Sciences Investors Stock Up 0.9%

Shares of NYSE:HQL opened at $17.87 on Wednesday. The company has a 50 day moving average of $16.88 and a 200-day moving average of $16.93. abrdn Life Sciences Investors has a twelve month low of $11.88 and a twelve month high of $18.10.

abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, February 20th were paid a $0.56 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a $2.24 dividend on an annualized basis and a dividend yield of 12.5%. This is an increase from abrdn Life Sciences Investors's previous quarterly dividend of $0.50.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors NYSE: HQL is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.